Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -35.57
- Piotroski Score 2.00
- Grade Buy
- Symbol (CYCN)
- Company Cyclerion Therapeutics, Inc.
- Price $3.66
- Changes Percentage (-31.2%)
- Change -$1.66
- Day Low $3.33
- Day High $5.45
- Year High $9.47
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/03/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.55
- Trailing P/E Ratio -0.56
- Forward P/E Ratio -0.56
- P/E Growth -0.56
- Net Income $-21,015,000
Income Statement
Quarterly
Annual
Latest News of CYCN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cyclerion Therapeutics, Inc. (CYCN) Stock Price, News, Quote & History - Yahoo Finance
Cyclerion Therapeutics focuses on developing treatments for serious diseases, such as Olinciguat and Praliciguat, sGC stimulators in clinical trials for cardiovascular and kidney diseases. Established...
By Yahoo! Finance | 3 days ago -
CYCN Stock Price | Cyclerion Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Cyclerion Therapeutics focuses on developing human therapeutics, specifically sGC stimulators that enhance cyclic guanosine monophosphate production. Founded in 2018, the company is based in Cambridge...
By MarketWatch | 4 days ago